VIR BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.23 USD | +7.86% |
|
+3.52% | -18.19% |
| Apr. 26 | Cytokinetics Appoints Sung Lee as CFO | MT |
| Apr. 18 | Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024 | CI |
Presentation Operator MessageOperator (Operator)Hello. Welcome to Vir Biotechnology's Fourth Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
8.23
USD
Average target price
29.5
USD
Spread / Average Target
+258.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.19% | 1.12B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VIR Stock
- News Vir Biotechnology, Inc.
- Transcript : Vir Biotechnology, Inc., Q4 2023 Earnings Call, Feb 22, 2024
